CARsgen pancreatic cancer therapy accepted for ESMO congress

CARsgen Therapeutics' satri-cel, an autologous CAR T-cell product, has had preliminary results from its Phase Ib registrational clinical trial for pancreatic cancer adjuvant therapy accepted for poster presentation at the European Society for Medical Oncology Congress 2025.

Satri-cel, which targets Claudin18.2, is a potential first-in-class treatment. CARsgen's New Drug Application for satri-cel in advanced gastric/gastroesophageal junction adenocarcinoma was accepted by China's NMPA in June 2025, receiving Priority Review and Breakthrough Therapy Designation.